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IntroductIon 
Over 230 million people worldwide undergo surgery 
each year, with this number increasing annually [1]. More 
than 80% of surgical patients experience acute postop-
erative pain, including about 75% who rate its intensity as 
moderate, severe or extreme. According to the available 
data, less than half of surgical patients report adequate 
postoperative pain relief. 
 Surgery-related trauma usually induces postoperative 
pain which should be alleviated as quickly and effectively 
as possible. According to statistics, clinical management of 
postoperative pain is far from being perfect, despite sig-
nificant advancements in evidence-based knowledge [2–4]. 
Severe pain is associated with decreased patient satis-
faction, delayed post-surgery ambulation, the development 
of chronic postoperative pain, increased incidence of severe 
complications (including pulmonary and cardiac) and higher 
postoperative morbidity and mortality [5–9]. Therefore, it 
is essential to properly identify the surgical procedures in-
ducing severe pain and to optimally tailor the strategy of 
postoperative analgesia to the patient’s needs and surgical 
procedures [10]. 
German researchers [11] have put forward a hypothesis 
that a systematic and standardised comparison of pain fol-
lowing all surgeries can help to identify the procedures 
resulting in severe postoperative pain. The results of their 
study are surprising. In cases of extensive thoracic and ab-
dominal surgeries, the NRS score was low (≤ 4). The percent-
age of advanced methods of analgesia, including block 
analgesia, used in such procedures was over 50%. Although 
the severity of pain following laparoscopic procedures was 
significantly higher, patients received relatively low doses of 
postoperative opioids or did not receive them at all (72%). 
The above results show that in many procedures, the extent 
of the incision and range of surgery-related trauma are 
not directly associated with the intensity of postoperative 
pain. According to the authors, the surgical procedures with 
poorly controlled postoperative pain include tonsillectomy, 
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haemorrhoidectomy with plastic reconstruction, appendec-
tomy and laparotomy cholecystectomy.
Acute pain management is based on a proper assess-
ment of its severity being performed several times a day, 
individual titration of analgesics and the minimisation of 
adverse effects. However, it has been demonstrated that 
in many cases the severity of pain is erroneously assessed 
by the medical personnel, which translates into improper 
titration and dosing of drugs and indirectly affects the per-
centage of adverse reactions associated with pain manage-
ment [12]. 
The mechanisms of development of acute postoperative 
pain are more complex than earlier believed while adequate 
pain management requires much more than just opioids. 
Therefore, it is not surprising that there is a comprehensive 
scientific evidence base that provides guidelines for postop-
erative pain management. One of the documents available 
is the fourth edition of Acute Pain Management: scientific 
evidence, published by the Australian and New Zealand 
College of Anaesthetists [13]. The size of this guideline sum-
mary reflects the complexity of the issue being discussed. 
It contains 650 pages, assesses over 8,500 scientific reports 
and condenses an enormous amount of information into 
669 key recommendations.
The assumption of the working group updating the 
Polish guidelines was to collect the scientific reports re-
garding acute postoperative pain that appeared after the 
publication of the previous edition of Polish guidelines 
for acute postoperative pain management (2014), in or-
der to collate the European, American and New Zealand 
recommendations published since then and to prepare 
updated guidelines for postoperative pain management. 
Following the procedure-specific postoperative pain 
management (PROSPECT) assumptions, our manage-
ment guidelines in the selected surgical procedures were 
formulated, albeit without categorisation of individual 
procedures. The authors of the present guidelines have 
divided the material into three major parts regarding the 
current state of knowledge on the drugs used for acute 
pain therapy, general recommendations for postopera-
tive pain therapy. 
The objective of this new version of the recommenda-
tions is also to draw attention to the fact that postoperative 
pain management is not merely a humanitarian task aimed 
at reducing patients` suffering and improving satisfaction 
with the treatment received, but also significantly reduces 
post-surgery morbidity and, most likely, post-surgery mor-
tality. Moreover, early rehabilitation and shortened hospital 
stays are associated with economic benefits for health care 
institutions, which is also of considerable importance [14].
The literature material collected and used for prepara-
tion of the majority of the recommendations was classified 
according to grades of recommendation (Table 1) and levels 
of evidence (Table 2) [15]. 
oPIoIdS For PoStoPErAtIVE PAIn rELIEF
Opioids are an important group of analgesics used for 
the management of acute and chronic pain syndromes. They 
are an effective tool in treating moderate and severe pain of 
various aetiologies, provided that their use is supported by 
good knowledge of their mechanisms of action, potential 
adverse effects they can induce, as well as interactions with 
other drugs simultaneously administered. Opioids act on 
three types of opioid receptors, namely MOR (mu), DOR 
(delta) and KOR (kappa). Opioid analgesics used in everyday 
clinical practice differ in their affinity to individual types of 
opioid receptors, interactions with these receptors (agonists, 
partial agonists, antagonists), strength of action, clinical 
efficacy and safety profiles. It is essential to know these 
differences in terms of the efficacy of individual opioids 
and the adverse reactions they can induce. Additionally, 
significant individual differences in responses to particular 
opioids are observed. Opioids affect the functioning of many 
systems and organs thus inducing specific clinical effects. 
Table 1. Grades of recommendation 
I — strongly recommended Scientific data and generally accepted opinions prove that the therapeutic management is beneficial, useful 
and effective. 
II Scientific data and opinions regarding the usefulness and efficacy of therapeutic management are 
inconsistent 
IIa — somewhat recommended Scientific data and opinions speak in favour of usefulness and efficacy
IIb — may be considered Usefulness or efficacy poorly confirmed by scientific data and opinions
III — strongly not recommended/ 
/definitely to be avoided 
Scientific data demonstrate that therapeutic management is neither useful nor effective; in some cases can 
even be harmful
Table 2. Levels of evidence according to [15]
A Data from numerous randomised controlled studies or 
meta-analyses
B Data from one randomised controlled study or non-
randomised studies
C Data from small-sized studies, retrospective studies or 
registers
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They exert analgesic effects, influence mood and behaviour 
and affect the functioning of the respiratory, cardiovascular, 
gastrointestinal, neuroendocrine and immune systems. It 
should be remembered that the majority of opioids cause 
immunosuppression, which can result in an increased risk of 
postoperative infections [16] and possible opioid-induced 
hyperalgesia (opioid paradox), manifesting itself as an in-
creasingly severe pain despite opioid dose escalation [17]. 
An increasing number of studies in the literature demon-
strate a higher probability of neoplastic disease progression 
in patients undergoing surgical oncological procedures 
being treated with opioids in the intra- and postoperative 
period, as compared with patients subjected to block anaes-
thesia [18]. However, the above data need to be confirmed 
by large population-based studies. 
The most common adverse effects associated with opi-
oid analgesics include nausea, vomiting, sedation, constipa-
tion, pruritus, and respiratory depression [19]. Due to a wide 
spectrum of opioid-induced adverse reactions, modern 
perioperative care promotes management methods and 
strategies aimed at reducing the opioid doses required 
yet providing appropriate efficacy of postoperative pain 
therapy and patient comfort. This aim can be achieved us-
ing multimodal analgesia, in which block anaesthesia tech-
niques and pharmacotherapy with non-opioid analgesics 
and co-analgesics (lidocaine, ketamine, gabapentinoids) 
are essential [20]. 
 In the postoperative period, opioids can be adminis-
tered via a variety of routes; intravenous and oral routes 
are most commonly used, while in cases of nerve blocks 
the perispinal (epidural or subarachnoid) or perinervous 
route can be applied. It is worth emphasising that analge-
sics should not be administered intramuscularly for many 
reasons, including those which are obviously humanitarian. 
Furthermore, the subcutaneous route is not recommended 
due to body cooling commonly observed in the immedi-
ate postoperative period and unreliable drug absorption, 
thus difficult-to-anticipate analgesic effects. After extensive 
surgical procedures, opioids are most commonly adminis-
tered intravenously due to excellent possibilities of adjusting 
their dose to the severity of pain. The optimal management 
strategy is to determine the most effective opioid dose 
by titration, i.e. the administration of low doses at short 
intervals until the pain is satisfactorily relieved, followed 
by continuous intravenous infusions. Titration is mainly 
recommended in patients with extremely severe pain in 
order to provide quick control, as well as in patients treated 
with potent opioids who additionally require many rescue 
doses of opioids. In practice, in cases of morphine titration, 
1-2mg of i.v. morphine is administered at several-minute 
intervals (every 3-5 minutes) until significant satisfactory 
pain relief has been provided or adverse reactions have 
Table 3. Doses of the opioid drugs most frequently used with patient-
controlled analgesia in adult patients [19]
Opioid Bolus dose Refraction time (min)
Morphine 0.5–2.5 mg 5–15
Oxycodone 0.03 mg kg-1 5–10
Fentanyl 0.02–0.05 mg 5–10
Nalbuphine 1–3 mg 6–10
Tramadol 10–25 mg 5–10
occurred. Subsequently, based on the total analgesic dose 
and half-life of a drug (in this case - morphine), an hourly 
demand can be calculated. For instance, if the dose needed 
for effective analgesia is 12 mg of morphine, the patient 
should be administered a continuous intravenous infusion 
at a dose of 2 mg per hour – the half-life of morphine is 3-4 
hours, which means that during that time half of a saturat-
ing dose (6 mg) has to be given to maintain the therapeutic 
concentration of morphine. Doses of the most common 
opioid drugs used with patient-controlled analgesia (PCA) 
in adults are presented in Table 3 [19]. 
In the immediate postoperative period, short-acting opi-
oids are preferable due to better possibilities of modification 
of the analgesic dose; long-acting and controlled release 
preparations should be used during the following postopera-
tive days when the pain being experienced is more stable. 
To convert intravenous doses of morphine into oral 
doses, a ratio 1:3 is used, i.e. if the daily demand for i.v. 
morphine is 20 mg, the equivalent oral dose will be 60 mg. 
For oxycodone, this ratio is 1:2. Once the demand for mor-
phine has been titrated, morphine can be replaced by any 
opioid analgesic characterised by the desirable therapeutic 
and pharmacokinetic profile and the optimal spectrum of 
adverse effects for a particular patient. 
The substitution of one opioid drug for another, called 
the rotation of opioids, is often required due to the inef-
fectiveness of treatment, changes in the nature of pain, or 
the occurrence of adverse reactions. The pharmacotherapy 
of pain uses the term of equianalgesic doses, which are 
defined as the doses of various opioids inducing the same 
analgesic effect. Table 4 presents equianalgesic doses of 
the most common opioid analgesics. The most important 
opioid drugs used in everyday practice are listed in Table 5.
UNRECOMMENDED OPIOID DRUGS
PETHIDINE
The current standards of acute and postoperative pain 
management in Poland and worldwide (American Pain Soci-
ety 2016) do not recommend pethidine. The recommenda-
tion is justified and concerns its efficacy, as well as safety. 
Pethidine is a synthetic analgesic showing weaker analge-
sic effects, as compared with morphine. Besides affecting 
176
Anaesthesiol Intensive Ther 2018, vol. 50, no 3, 173–199
Table 4. Equianalgesic doses of opioid drugs 
Opioid Intravenous dose Oral dose
Morphine 10 mg 30 mg
Tramadol 100 mg 150 mg
Oxycodone 7.5–10 mg 20 mg
Fentanyl 0.1 mg –
Buprenorphine 0.4 mg 0.8 mg  
(sublingual tablets)
Tapentadol – 100 mg
Methadone 1 mg 3 mg
Nalbuphine 10 mg –
mu-opioid receptors, it exerts a cholinolytic effect and has 
locally anaesthetic action. After its parenteral administra-
tion, the analgesic effect is maintained for about 2–3 h and 
is individually variable. Norpethidine, an active metabolite 
of pethidine, is characterised by a long half-life of 8–21 h; 
although it has half the analgesic potency of pethidine, it 
exerts neurotoxic effects. Due to the short analgesic effect 
of pethidine and a long half-life of its neurotoxic metabolite, 
the latter can accumulate at repeated doses of pethidine. 
The prolonged half-life of norpethidine is particularly im-
portant in the paediatric population. Moreover, the use of 
pethidine during delivery may lead to the newborn`s expo-
sure as a result of placental drug transfer, which is likely to 
deteriorate the neonate’s neurological status or even induce 
seizures. It should be emphasised that the blood-brain bar-
rier in newborns and infants is not fully functionally efficient 
and therefore many drugs can more profoundly penetrate 
the CNS during this period, inducing post-drug adverse re-
actions, as compared with the population of adult patients. 
Therefore, pethidine should not be used as an analgesic 
during deliveries.
The adverse effects of pethidine may also be observed 
in the geriatric population. Patients over 65 years of age 
often have impaired liver and kidney functions compared 
with younger individuals, which additionally favours the 
accumulation of pethidine resulting from the prolonga-
tion of its half-life. Moreover, the administration of pethi-
dine in this group increases the risk of CNS-associated 
adverse effects, including agitation, confusion, motor 
disturbances, dizziness, nausea and vomiting. Of note 
is the fact there are no data proving the higher efficacy 
of pethidine in the pharmacotherapy of pain compared 
with other opioids. Numerous studies have demonstrated 
that pethidine can be successfully replaced with other 
safer opioids that do not yield toxic metabolites, whose 
half-life and analgesic effects are substantially longer, as 
compared with pethidine. 
 
PENTAZOCINE
Pentazocine is a kappa-opioid receptor agonist; there-
fore, besides relatively weak analgesic action (5–10 times 
weaker than that of morphine), it also shows hallucinogenic 
and dysphoric effects. For this reason, this drug should not 
be used for postoperative pain management [19]. 
non-oPIoId AnALGESIcS For PoStoPErAtIVE 
PAIn MAnAGEMEnt
In patients with acute and postoperative pain, non-
opioid analgesics are recommended when the severity of 
pain does not exceed NRS = 4. They can be administered as 
monotherapy; in cases of more severe pain, they should be 
part of multimodal analgesia, which allows one to broaden 
the spectrum of analgesic effects of other analgesics and to 
reduce the total dose of opioid analgesics. 
In any nociceptive pain (mechanical, inflammatory, 
visceral), nonsteroidal anti-inflammatory drugs (NSAIDs) 
are effective. Paracetamol, which has no anti-inflamma-
tory effects, is effective only in somatic nociceptive pain 
[19, 21, 22]. Metamizole is additionally characterised by 
central spasmolytic action; therefore, it is particularly ef-
fective in visceral nociceptive pain [22]. When NSAIDs are 
combined with paracetamol and/or metamizole, an additive 
analgesic effect is achieved. 
The selection of NSAID for the treatment of postop-
erative pain should be individualised; the following criteria 
should be considered:
 — onset of analgesic action,
 — duration of analgesic effects 
 — effective analgesic dose 
 — contraindications and risk of upper gastrointestinal, 
cardiovascular and renal complications 
 — liver and kidney function,
 — other drugs used simultaneously and potential interac-
tions with non-opioid analgesics [21–23].
Intramuscular and rectal routes of administration of 
non-opioid analgesics are not recommended due to a long 
latency period and the fluctuating profile of analgesic ef-
fects (strong recommendation, I A) [22–24]. As intravenous 
drugs induce the quickest analgesic effects in acute pain, 
certain available i.v. drugs are recommended. Non-opioid 
analgesics achieve T max (max. concentration) most quickly 
after i.v. administration, which directly correlates with the 
onset and peak of analgesic action [22–24]. Considering the 
pathomechanism of action, the location of pain, contraindi-
cations and limitations, the first-line drugs recommended 
for the treatment of acute and postoperative pain include 
dexketoprofen, ketoprofen, paracetamol and metamizole 
[22–24]. When analgesics can be administered orally, drugs 
in the form of granulates, soluble tablets and orodispersive 
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tablets (ODTs) are preferable due to the speed of analgesic 
action. The soluble formulations induce quicker analgesic 
effects than tablets, as once they are dissolved, the absorp-
tion is immediate and no time is needed to disintegrate the 
tablet and release an analgesic from it. Moreover, soluble 
formulations of NSAIDs available on the market may be 
taken on an empty stomach (e.g. dexketoprofen in the form 
of a soluble granulate for oral administration). The ceiling 
doses of all non-opioid analgesics have been determined, 
above which no increase in the analgesic effect is observed 
while the risk of complications is significantly higher [22–25] 
(Table 6).
The maximum daily doses of non-opioid analgesics are 
as follows: 
 — 5 g for metamizole, 
 — ≤ 15 mg kg-1 mc.-1 for both oral and intravenous 
paracetamol; intravenously, the drug can be admin-
istered at a maximum of 4 times a day (in a patient 
weighing 80 kg, the daily dose of 4 g should not be 
exceeded) [26].
The use of paracetamol is associated with reduced sever-
ity of pain thus reduced consumption of opioid analgesics 
[26]. A single pre-emptive intravenous dose administered 
10–30 minutes before skin incision reduces the severity 
of postoperative pain, decreases the incidence of nausea 
and vomiting and contributes to reduced use of opioid 
analgesics in the postoperative period, which diminishes 
the severity of adverse effects characteristic of this group 
of opioid analgesics. Of note is the fact that during the first 
post-surgery days, depending on the degree of pain severity 
de-escalation, the intravenous route is preferred; due to its 
pharmacokinetic/pharmacodynamic (PK/PD) profile, this 
route is associated with achieving higher concentrations 
of the drug, which translates into a more optimal profile of 
efficacy, as compared with the oral route, while it should 
be remembered that pharmacokinetics of paracetamol are 
linear [26]. 
Moreover, oral combinations of non-opioid analgesics 
are recommended for the treatment of acute pain. There 
Table 6. Maximum daily doses of nonsteroidal anti-inflammatory drugs 
most commonly used for acute pain 
Drug Maximum daily dose
Dexketoprofen 150 mg*
Ketoprofen 200 mg
Ibuprofen 3200 mg
Naproxen 1500 mg
Nimesulide 200 mg
Lornoxicam 16 mg
Diclofenac 150 mg
*p.o. max. 75 mg, i.v. max 150 mg
are such combinations available on the market which 
show an additive analgesic effect, e.g. paracetamol with 
ibuprofen. In practice, this means that such a combination 
supplements the pharmacological effects, broadening the 
spectrum of analgesic action while simultaneously only 
slightly potentiating this action. Furthermore, combinations 
showing hyperadditive effects are available, e.g. dexketo-
profen + tramadol, paracetamol + tramadol, which means 
that the spectrum of analgesic effect is not only substan-
tially supplemented and broadened but also the effect is 
markedly potentiated [22–24]. Acute and postoperative 
pain is also treated with such NSAIDs as selective COX-2 
inhibitors. In Poland, oral forms of celecoxib and etoricoxib 
are available. According to the Cochrane Collaboration of 
2013, celecoxib administered in a single dose after surgery 
(orthopaedic or dental procedures) effectively reduces the 
pain experienced and lengthens the time to administra-
tion of the next analgesic — median 6.6 h at 200 mg, 8.4 h 
at 400 mg and 2.3 h when a placebo is used. The adverse 
reactions have been observed in a comparable percentage 
of patients in the celecoxib and placebo groups and were 
mild or moderate [24, 25]. Schroer et al. [26], who studied 
the use of celecoxib for 6 weeks in 107 patients subjected 
to knee endoarthroplasty, demonstrated a lower consump-
tion of opioids in the perioperative period and better VAS 
scores. Moreover, in the group receiving celecoxib over one 
post-surgery year, the range of motion at the knee joint was 
greater [24, 25]. Similar results were reported by other cen-
tres. The meta-analysis of studies regarding the prevention 
of extra-skeletal ossifications after hip endoarthroplasty has 
revealed that the efficacy of celecoxib in preventing extra-
skeletal ossifications is comparable to that of indometacin. 
Furthermore, celecoxib was the only drug reducing the risk 
of gastrointestinal adverse effects (as compared with indo-
metacin) [24, 25], which is extremely important in surgical 
patients who have to be subjected to obligatory assessment 
and receive pharmacological prophylaxis in justified cases 
of venous thromboembolic disease. It is worth pointing out 
that the use of celecoxib does not exclude upper gastro-
intestinal complications, including perforation. However, 
when applied according to experts’ recommendations, it 
significantly reduces their risk, compared with non-selective 
cycloxygenase inhibitors. Another drug that has been found 
to provide adequate acute and postoperative pain manage-
ment is etoricoxib [24, 25]. 
PARACETAMOL
Based on the most recent studies concerning its mecha-
nism of action, paracetamol is considered a pro-drug, which 
interacts with the endocannabinoid system thanks to its 
active metabolites. In the brain and spinal cord, paracetamol 
has been found to undergo deacetylation to p-aminophe-
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nol, which reacts with arachidonic acid via fatty acid amide 
hydrolase (FAAH) to form an active metabolite of this drug, 
i.e. N-arachidonoylphenolamine (AM404) [27, 28], that does 
not directly affect the cannabinoid receptors but indirect-
ly increases the activity of the endocannabinoid system. 
On the one hand, this compound is a potent activator of 
the transient receptor potential cation channel subfam-
ily V member 1 (TRPV1), which is a ligand of cannabinoid 
type 1 (CB1) receptors; on the other hand, being an inhibi-
tor of endogenous cannabinoid (anandamide) reuptake, it 
increases the endogenous pool of these compounds [29]. 
Endogenous cannabinoids, e.g. anandamide, exert antino-
ciceptive effects both at the level of the spinal cord and the 
brain. Moreover, cannabinoids substantially reduce body 
temperature by activating CB1 receptors in the pre-visual 
hypothalamic area [27, 29, 30]. It is well known that anal-
gesic derivatives of aniline show similar effects as those of 
cannabinoids, e.g. improved mood, mental relaxation and 
tranquillity. To date, such properties of paracetamol have not 
been demonstrated, although some authors attribute slight 
sedative effects to it. Moreover, AM404 has been found to 
show dose-dependent COX-1 and COX-2 inhibitory effects 
[27, 28, 30, 31]. This mechanism may be particularly impor-
tant in the brain areas with high concentrations of FAAH, 
e.g. in the mesencephalic nucleus of the trigeminal nerve 
or in the primary sensory neurones, as the production of 
AM404 in these areas is increased, which can to some extent 
explain the inhibitory activity of paracetamol toward CNS 
cycloxygenases. An alternative mechanism of the analgesic 
effects of paracetamol could be the inhibition of nitric oxide 
(NO) formation. The L-arginine/NO pathway, activated by 
substance P and N-methyl-D aspartic acid (NMDA) recep-
tors, leads to the synthesis of NO, which is an important 
neurotransmitter in the nociceptive processes in the spinal 
cord [30–32].
In conclusion, paracetamol acts at all levels of conduc-
tion of pain stimuli, starting with the receptors in tissues, 
through the spinal cord to the thalamus and cerebral cortex, 
where the pain sensations are received. The mechanism of 
analgesic action of paracetamol is complex and still several 
options are considered, including the effects on both periph-
eral (inhibition of COX activity) and central (COX, descending 
serotonergic inhibitory pathways, L-arginine/NO pathway, 
the cannabinoid system) anti-nociceptive processes and 
the “oxidoreductive” mechanism. Currently, the inhibitory 
effects of paracetamol on COX-3 are no longer emphasised 
as COX-3, which occurs in laboratory animals, has not been 
detected in humans [32]. 
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
Nonsteroidal anti-drugs (NSAIDs) belong to the group of 
non-opioid analgesics of anti-inflammatory, analgesic and 
antipyretic action. In addition to inhibiting the synthesis of 
prostaglandins, they may affect other pathophysiological 
processes involved in inflammatory nociceptive pain. This 
group of drugs exerts analgesic and anti-inflammatory ef-
fects via inhibition of inducible nitric oxide synthase expres-
sion and of NF-kappa B activation, activation of the system 
of lipoxines, as well as inhibition of substance P activity. 
Additionally, the action of NSAIDs may result from activa-
tion of supraspinal cholinergic pathways and of the system 
of endogenous opiate-similar peptides. 
In patients treated with NSAIDs, contraindications and 
limitations resulting from cardiovascular, kidney, upper and 
lower gastrointestinal diseases should be taken into ac-
count. As far as perioperative interactions are concerned, it 
is worth remembering that their concomitant use with the 
drugs belonging to selective serotonin reuptake inhibitors 
(SSRIs) and serotonin and norepinephrine reuptake inhibi-
tors (SNRIs) increases the risk of perioperative bleeding. Like-
wise, their concomitant administration with loop diuretics 
increases the risk of nephrotoxicity. Only one NSAID should 
be applied at a time, as more NSAIDs do not increase the 
therapeutic efficacy while significantly increasing the risk of 
adverse effects. Acute and postoperative pain is also treated 
with such NSAIDs as selective COX-2 inhibitors. In Poland, 
oral celecoxib and etoricoxib are currently available. 
METAMIZOLE
Among the drugs having analgesic, antipyretic and re-
laxing effects, metamizole is most commonly used in Poland 
[33–35]. Metamizole belongs to the group of non-opioid 
analgesics. Unlike NSAIDs, it shows no anti-inflammatory ac-
tion; however, its analgesic effect cannot be compared with 
that of any other analgesic [35–38]. In 2012, new metamizole 
metabolites were identified, which changed the general ap-
proach to the use of metamizole in ambulatory and clinical 
practice. This regards not only wider clinical indications but 
also new options for combined treatment [35, 39, 40]. The 
metabolites of metamizole inhibit the synthesis of prosta-
glandins, mainly by inhibiting COX-1 and COX-2 activity but 
also by inhibiting substance P-induced nociception [35, 36, 
39–42]. Additionally, metamizole affects the cannabinoid 
system, producing analgesic and antipyretic effects [35, 
43, 44]. Furthermore, the relaxing smooth muscle effect 
results from the inhibition of adenosine reuptake in the CNS 
structures and the influence on the cannabinoid system. 
The relaxing effect is particularly important for the man-
agement of colic and visceral pain [36, 44, 45]. Metamizole 
displays a synergism of action with NSAIDs, paracetamol 
and opioid analgesics. It is recommended for acute pain, 
including post-trauma pain and as a relevant element of 
the combined treatment of pain. Considering new data 
demonstrating its safety, metamizole may be used both in 
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adult and paediatric populations. In 2014, metamizole was 
included in the Austrian standards regarding its use in the 
paediatric population, which has consolidated the opinion 
about its safety in this population. Furthermore, in Poland 
there are some approved therapeutic products containing 
metamizole that may be used in infants over 3 months of 
age. According to recent cohort and observational studies, 
metamizole-induced agranulocytosis is rare while its inci-
dence is comparable to that induced by other non-steroidal 
analgesics [36, 39, 46]. The use of metamizole is associated 
with a low risk of interactions with other drugs applied con-
comitantly. As the interaction with cyclosporine is clinically 
important, great caution should be exercised in patients 
receiving both drugs simultaneously. 
AdJuVAntS For AcutE PAIn MAnAGEMEnt
Note: 
1. The information provided below does not include the 
use of the drugs discussed in regional anaesthesia. 
2. The use of the drugs discussed below as adjuvants for 
pain relief/components of multimodal analgesia is out-
side the summary of therapeutic product characteristics 
(except lidocaine). 
LIDOCAINE
Intravenous lidocaine used in the perioperative period 
as part of multimodal analgesia allows one to administer 
lower doses of opioids or to abandon them completely. 
It significantly decreases the severity of pain in the early 
postoperative period at rest and during physical activity 
(deep breaths, coughing). Moreover, its use significantly 
reduces the incidence of nausea and vomiting, accelerates 
the restoration of postoperative gastrointestinal function 
(particularly after abdominal surgeries) and shortens hos-
pitalisation stays ([47–51] meta-analyses of randomised 
controlled trials [RCT] = level I]). Furthermore, perioperative 
intravenous infusions of lidocaine have been demonstrated 
to induce preventive analgesia (analgesia of 5.5-times longer 
action than the half-life of lidocaine, i.e. > 8 h since the 
discontinuation of its administration ([52] meta-analysis of 
RCT = level I). 
According to the results of clinical trials, intravenous 
infusions of lidocaine are predominantly indicated in open 
and laparoscopic abdominal surgical procedures. Few clini-
cal trials demonstrate the benefits of intravenous infusions 
of lidocaine in patients subjected to prostate, breast, tho-
racic and multi-level spinal procedures. No benefits have 
been confirmed in patients after cardiac surgeries, laparo-
scopic nephrectomy, transabdominal hysterectomy or hip 
endoarthroplasty [53]. 
Optimal dosage, initiation and duration of lidocaine 
intravenous infusion have not yet been determined. The 
available clinical trials show that the intravenous infusion of 
lidocaine is initiated at least 30 minutes before skin incision 
(induction of preventive analgesia), up to 30 minutes before 
or during the induction of anaesthesia. The most common 
saturating bolus dose is 1.5 mg kg-1 (dose range 1–3 mg 
kg-1), while the lidocaine dose in an infusion ranges from 
1.5 to 3.0 mg kg-1 h-1. Doses should be calculated based on 
the ideal body weight (IBW), which is particularly important 
in obese patients. The infusion ends at the completion of 
surgery (in most cases) or is continued in the postopera-
tive period — most commonly over 24 hours or up to 48 
h [54]. With the above doses, the plasma concentration of 
lidocaine can fluctuate between 1 and 5 µg mL-1. Lidocaine 
administered in such doses does not block peripheral nerve 
conduction. From the pharmacological point of view, in-
travenous lidocaine is a modulator of conduction in the 
peripheral nervous system and of peripheral and central 
sensitisation [55]. 
The dose of lidocaine should be reduced in cases in 
which the free drug fraction is increased, namely: acidosis, 
hypercapnia, hypoxia, hypoproteinaemia, and impaired liver 
and kidney functions. In patients with heart, liver and/or 
kidney failure, the dose of lidocaine should be reduced and 
the cardiovascular system should be monitored [56]. 
The infusion of lidocaine is contraindicated when other 
modalities of regional anaesthesia are applied, especially 
when a local anaesthetic is administered in a bolus or high 
doses (e.g. epidural anaesthesia, plexus anaesthesia). An infu-
sion may be initiated 4-8 h after bolus administration of the 
local anaesthetic, if required. In cases of failed epidural anaes-
thesia, once the continuous infusion into the epidural space is 
stopped and no bolus doses are given into the epidural space, 
the continuous intravenous infusion of lidocaine can be initi-
ated immediately, albeit without an intravenous bolus [57]. 
Lidocaine in a continuous infusion at a dose of ≥ 2 mg 
kg-1 h-1 reduces pain severity at rest within the first 4 post-
operative hours [58]. According to one study in which 1.5 
mg kg-1 h-1 lidocaine in a continuous infusion was used, 
there were no differences in pain severity compared with 
the control group; however, the demand for morphine was 
found to be lower while pain on movement was found to be 
of lesser severity. The differences occurred on the second 
postoperative day and were most pronounced during the 
third postoperative day [58]. The above observations are 
consistent with the results of laboratory tests, which reveal 
that the infusion of lidocaine inhibits the development of 
central hyperalgesia in three phases. The first acute phase 
of inhibition lasts 30-60 minutes after the completion of the 
infusion; the second transient phase, up to 6 hours; while the 
third phase of prolonged inhibition develops slowly within 
24 h after the completion of the infusion and is maintained 
for 21 days [59]. 
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In acute neuropathic pain (which can be a component of 
postoperative pain), the action of lidocaine involves mainly 
the inhibition of generation of ectopic, spontaneous excita-
tions in the damaged nerves. Such effects occur at a plasma 
concentration of lidocaine 40 times lower than the concen-
tration that is required to inhibit the conduction of nerve 
excitations in undamaged nerves [60]. 
The mechanism of action of lidocaine in postoperative 
pain differs from the mechanisms of its action in neuropathic 
pain and is not fully elucidated. It does not affect acute no-
ciceptive pain [61–64]. Moreover, lidocaine does not signifi-
cantly influence the thermal and mechanical pain threshold 
in intact tissues [64, 65]. It acts anti-hyperalgesically inhibit-
ing peripheral sensitisation by affecting C-fibre nociceptors 
(primary hyperalgesia), as well as central sensitisation at 
the spinal cord level (secondary hyperalgesia). The central 
effects predominate. The perioperative infusion of lidocaine 
is most effective in surgeries associated with the develop-
ment of increased central hyperalgesia.
Two large groups of C-fibre nociceptors are distin-
guished, namely: those mechanically and heat-responsive 
(CMH); and those unresponsive to mechanical and heat stim-
ulation (CMiHi), called “sleeping” nociceptors, which become 
stimulus-responsive after their sensitisation (a decrease in 
the excitation threshold) by mediators of inflammation 
(reduction in nociceptors). The sensitisation of polimodal 
nociceptors leads to temporal summation of nociceptive 
stimuli while the recruitment of “sleeping” nociceptors leads 
additionally to spatial summation [66, 67]. 
Lidocaine preferentially affects the recruited nocicep-
tors and inhibits their activity (by blocking sodium channels 
Nav 1.7, 1.8 and 1.9), thus decreasing primary hyperalgesia. 
It does not affect CMH nociceptors; the threshold to me-
chanical and thermal stimuli (including acute nociceptive 
pain) remains unchanged and can mask the analgesic ef-
fect of lidocaine [68–70]. Stronger inhibition of sensitised 
“sleeping” CMiHi receptors by low concentrations of lido-
caine seems to be the cause of the high efficacy of intra-
venous infusions of lidocaine in gastrointestinal surgical 
procedures. In abdominal surgeries with extensive tissue 
damage, potent stimulation of nociceptors responsive 
to chemical stimuli and the simultaneous sensitisation 
of CMiHi nociceptors are observed. By inhibiting these 
nociceptors, lidocaine reduces central hyperalgesia and 
postoperative pain [71].
Lidocaine acting at the spinal cord level inhibits synaptic 
conduction, thus reducing secondary hyperalgesia [72–74]. 
The synaptic conduction effects result from direct and in-
direct (inhibition of protein kinase C) blocking of NMDA 
receptors and neurokinin receptors. The inhibition of M3 
muscarinic and glycine receptors enhances the activity of 
the descending cholinergic antinociceptive system [75–77]. 
A relevant mechanism of lidocaine action in acute pain 
is its anti-inflammatory action (a more detailed description 
is beyond the scope of this paper) [78]. This drug limits 
the inflammatory reaction to surgery-related trauma by 
blunting the effects of proinflammatory factors. It inhibits 
granulocyte priming, which prevents the excessive release 
of proinflammatory cytokines and free radicals. The activity 
of mechanisms leading to the development of neurogenic 
inflammation is diminished at the site of tissue damage, 
which decreases peripheral sensitisation and primary hy-
peralgesia [79]. 
MAGNESIUM SULPHATE
Magnesium is an antagonist of NMDA receptors present 
in the peripheral and central nervous system [80]. The NMDA 
receptors are an important element of the glutamatergic 
system whose main neurotransmitter is glutamic acid (glu-
tamate). One of the functions of the glutamatergic system 
is the involvement in nociception. The excitation of NMDA 
receptors by glutamate causes an intracellular inflow of 
calcium ions and enhances the propagation of nociceptive 
impulsation. The concentration of NMDA receptors is par-
ticularly high in the anterior horns of the spinal cord. These 
receptors are associated with the development of central 
sensitisation clinically manifesting itself as hyperalgesia 
and allodynia [81, 82]. Besides inhibiting NMDA receptors, 
magnesium ions exert anti-inflammatory effects by decreas-
ing the plasma concentration of IL-6 and TNF-α. The anti-
inflammatory action can be involved in the reduction in 
central sensitisation [83]. 
Magnesium sulphate added to i.v. morphine reduces 
the daily demand for morphine (opioid-sparing effect) in 
the postoperative period. Although this does not affect 
the incidence of nausea and vomiting, it decreases the se-
verity of pain at rest, especially during the first 4–6 hours, 
at a maximum of up to 20–24 hours after surgery, and on 
movement up to 20–25 hours after surgery ([84] RCT meta-
analysis = level I, [85] RCT meta-analysis = level I, [86] RCT 
meta-analysis = level I, [87] RCT meta-analysis = level I [88], 
RCT meta-analysis = level I). The most pronounced reduction 
in daily demand for morphine was observed after urologic, 
gynaecological and orthopaedic procedures, as well as chol-
ecystectomies, large bowel procedures and coronary artery 
bypass grafting. 
The uniform doses of magnesium sulphate have not 
been determined to date. In most cases, an initial bolus 
of 50 mg kg-1 (range 30–50 mg kg-1) is used, followed by 
intravenous infusion of 10–15 mg kg-1 h-1 (range 6–25 mg 
kg-1 h-1) until the surgery has been completed, although in 
some studies the infusion was continued for 24–48 hours. 
The beneficial effects of magnesium sulphate in the post-
operative period were also observed in patients undergoing 
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subarachnoid anaesthesia ([89] RCT meta-analysis = level 
II, [90] RCT meta-analysis = level II, [91] RCT meta-analysis 
= level II]).
Magnesium ions can delay the restoration of neuromus-
cular transmission and induce bradycardia; nevertheless, 
the available data demonstrate that magnesium sulphate 
is an effective and safe complement of postoperative pain 
pharmacotherapy and should be considered as part of multi-
directional (multimodal) analgesia.
ALPhA-2-AdrEnoMIMEtIc druGS  
(α2-AdrEnErGIc rEcEPtor AGonIStS) 
Agonists of the α2-adrenergic receptor exert their ef-
fects by stimulating α2-receptors in the posterior horn of 
the spinal cord and supraspinally at the locus coeruleus.
The perioperative use of an α2-adrenergic receptor 
agonist, clonidine or dexmedetomidine, diminishes the 
intensity of pain in the postoperative period, enables reduc-
tions in opioid doses and decreases the incidence of nausea 
([92] RCT meta-analysis = level I]. The above drugs are most 
commonly used in premedication (orally or intravenously) 
and intraoperatively (intravenously); their supply can be 
continued in the postoperative period (repeated doses or 
continuous infusions). The optimal dosage has not yet been 
determined. 
Clonidine is most commonly administered as premedi-
cation at a dose of 3–5 µg kg-1 (30–90 minutes before in-
duction, orally or in a 30-60-minute intravenous infusion). 
Its supply can be continued in the intravenous infusion at 
a dose of 0.2–0.3 mg kg-1 h-1 [93–95].
Dexmedetomidine is used at an initial dose in intrave-
nous premedication (5–10 minutes to 30 minutes before 
induction) or intraoperatively in intravenous infusion at 
a dose of 0.5–2 µg kg-1 administered over 5–10 minutes. 
The intravenous supply of dexmedetomidine is continued 
intraoperatively and /or postoperatively at a dose of 0.2–0.5 
mg kg-1 h-1 [96–99].
The most common adverse effects limiting the use 
of α2-adrenergic receptor agonists include hypotension, 
bradycardia and sedation. 
GABAPENTINOIDS (α2δ LIGANDS) 
Gabapentinoids inhibit hyperalgesia and allodynia and 
only slightly affect nociception. They reduce hyperexcita-
tion of neurones in the posterior horns of the spinal cord 
(leading to central sensitisation) developing after traumatic 
tissue damage.
Two phases of gabapentinoid action are distinguished, 
namely rapid (30–60 min) and slow (10–20 h). According 
to the studies performed to date, the rapid phase seems 
essential for acute pain in the perioperative period, which is 
associated with the effects on surgically damaged neurones. 
In these neurones in the apparatus releasing a neurotrans-
mitter, the number of calcium channels increases and the 
cell excitation is up-regulated.
Gabapentinoids bind to a subunit of the α2δ presynaptic 
high-voltage-gated calcium channel (HVA-Ca2+), causing its 
inactivation. The above limits the axonal transport of active 
HVA-Ca2+ channels to the synapse in the spinal cord and 
reduces their number in the neurotransmitter-releasing 
apparatus, which results in a decreased intracellular in-
flow of calcium ions necessary to initiate the release of 
a stimulating neurotransmitter (e.g. substance P, a peptide 
connected with the calcitonin gene) from the presynaptic 
vesicles. Th  e reduced neurotransmitter release decreases 
the excitation of neurones, which results in quick emergence 
of the effects inhibiting the development of allodynia and 
hyperalgesia [100]. 
The perioperative use of gabapentin ([101] RCT meta-
analysis = level I, [102] RCT meta-analysis = level I]) and 
pregabalin ([103] RCT meta-analysis = level I]) improves 
the quality of analgesia at rest and on movement while 
reducing opioid requirements in the postoperative period. 
Gabapentin and pregabalin reduce the incidence of ad-
verse effects induced by opioids, especially vomiting, urine 
retention and nausea. According to the authors of a meta-
analysis regarding perioperative pregabalin, the drug can 
be particularly beneficial for patients undergoing surgical 
procedures associated with highly severe postoperative pain 
and indications for its use should be determined after the 
potential side effects have been considered [104].
The beneficial effects of gabapentin on the severity of 
postoperative pain and opioid consumption were observed 
irrespective of the type of surgery [102] and dose (within 
the range of 300–1200 mg) [101], although the authors 
of a meta-analysis performed later suggest doses in the 
range of 600–1200 mg [102]. Given the diversity of dosing 
protocols, it is difficult to recommend one of them. Based on 
one’s present knowledge, it seems justified to administer ga-
bapentin in premedication 2 hours before surgery at a dose 
of 600–1200 mg, taking into consideration possible adverse 
reactions (excessive sedation, dizziness, vision disorders). 
CORTICOSTEROIDS 
Generally, acute postoperative pain is considered to be 
inflammatory nociceptive pain. Depending on the type of 
surgery, a neuropathic component to acute postoperative 
pain may develop. During the late acute phase of postop-
erative pain, reversible neuropathic pain is even likely to 
predominate [105].
Tissue damage triggers the arachidonic acid cascade, 
ultimately leading to the formation of algesiogenic pros-
taglandins and leukotrienes. The key process for the ini-
tiation of the arachidonic acid cascade is the activation of 
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Figure 1. Scheme of the process of inhibiting phospholipase A2 activity by corticosteroids
phospholipase A2 (PLA2), which releases arachidonic acid 
directly from membrane phospholipids. Arachidonic acid 
is a substrate for cycloxygenase (COX) and lipoxygenase 
(LOX). COX catalyses the synthesis of prostaglandins while 
LOX catalyses the synthesis of leukotrienes. PGE2 and PGI2, as 
well as leukotrienes LBT4, are involved in the development 
of hyperalgesia.
Corticosteroids indirectly inhibit the activation of phos-
pholipase A2 by inducing the synthesis of lipocortine (an-
nexin A1). The inhibition of phospholipase A2 reduces the 
amount of substrate (arachidonic acid) available for cycloxy-
genase and lipoxygenase, which in turn results in reduced 
synthesis of prostaglandins and leukotrienes and finally 
produces anti-inflammatory effects [106]. 
Corticosteroids inhibit the formation and release of pro-
inflammatory cytokines IL-1, IL-2, IL-6, interferon gamma 
(IFN-γ) and tumour necrosis factor alpha (TNF-α). They sta-
bilise the cell membranes of neurones in the peripheral 
tissues and exert an antinociceptive effect at the spinal level.
The main mechanism of action of corticosteroids in-
volves binding to an intracellular receptor (glucocorticoid 
receptor — GR). Via the genomic mechanism, after binding 
the corticosteroid, the GR-ligand complex formed is trans-
ported (translocation) to the cell nucleus. In the nucleus, the 
complex acts directly and indirectly on DNA transcription 
and thus affects the expression of target genes and the syn-
thesis of proteins via transactivation or transrepression. The 
indirect inhibition of inflammatory response genes occurs 
by interacting with the transcription factors — activator pro-
tein 1(AP-1), nuclear factor kappa B (NF-κB) and interferon 
regulatory factor 3 (IRF-3) [107]. The onset of action via the 
genomic mechanism is slow (several hours) [108]. 
Via the non-genomic mechanism, the corticosteroid-
induced processes occur too quickly (minutes) to depend 
on the effects on DNA transcription. One such process is 
the inhibition of arachidonic acid release from membrane 
phospholipids (described above). During this short time cor-
ticosteroids are likely to modulate (stabilise) the excitability 
of the cell membrane and synaptic transmission by interact-
ing with ionotropic receptors, such as GABAA or NMDA, or 
with voltage-gated calcium or potassium channels [108].
The first clinical trials evaluating the effects of steroids on 
postoperative pain were carried out in patients after molar 
extractions in the 1980s [109, 110]. Since that time, many 
clinical trials have been published confirming the efficacy 
of steroids for reducing the severity of pain and opioid 
consumption in the postoperative period. Dexamethasone 
was used most frequently and methylprednisolone, beta-
methasone and hydrocortisone less frequently. 
Patients receiving dexamethasone reported lower in-
tensities of pain at rest and on movement and decreased 
opioid requirements in the postoperative period; the time 
to the first analgesic dose was found to be longer, a rescue 
analgesic dose was less frequently required and recovery 
room stays were shorter. The differences between the study 
and control groups were statistically significant, albeit clini-
cally slight. The pain intensity was reduced by about 10%, as 
compared with the control group. Opioid requirements dur-
ing the first 24 postoperative hours decreased by 10–13% 
([111] RCT meta-analysis = level I, [112] RCT meta-analysis 
= level I, [113] RCT meta-analysis = level I]). 
 Dexamethasone at a dose of 0.11–0.2 mg kg-1 reduces 
the pain intensity and opioid demand in the postoperative 
period. A lower dose does not exert such effects whereas 
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a higher dose is not more effective ([114] RCT meta-analysis 
= level I). The analgesic action of dexamethasone is stronger 
when administered 45–90 minutes before surgery ([113] RCT 
meta-analysis = level I, [114] RCT meta-analysis = level I]) 
A certain limitation to preoperative i.v. administration of 
dexamethasone might be a high incidence (50–70%) of 
strong, burning pain of the perineum, especially after the 
quick administration of a low volume. This can be prevented 
by diluting the drug in 50 mL 0.9% NaCl and giving it by an 
intravenous infusion for 10–15 minutes [113, 114].
 A single dose of dexamethasone has not been found to 
increase the incidence of infections or to delay postopera-
tive wound healing; however, during the first 24 postopera-
tive hours, the blood concentration of glucose is slightly yet 
statistically significantly higher ([111] RCT meta-analysis = 
level I, [114] RCT meta-analysis = level I, [113] RCT meta-
analysis= level I]).
The use of dexamethasone for postoperative pain relief 
is best documented in patients undergoing the following: 
maxillofacial procedures ([115] RCT meta-analysis = level I]); 
tonsillectomies (including those in children) [111] RCT meta-
analysis = level I, [116] RCT meta-analysis = level I]; thyroid 
surgeries [117] RCT meta-analysis = level I]; and knee and 
hip procedures [118] RCT meta-analysis = level I, [119] RCT 
meta-analysis = level I].
A dose of 0.1–0.2 mg kg-1 is most frequently used. For 
optimal analgesic effects, this should be administered about 
45–90 minutes before surgery. The analgesic effects are 
maintained for up to 24 hours. 
KETAMINE
 The basic management to maintain homeostasis in 
a surgical patient involves the provision of adequate analge-
sia and sedation, as well as the blockage of afferent transmis-
sion of stimuli (including those which are nociceptive) to the 
CNS, haemodynamic stability, appropriate tissue perfusion 
and abolition of reflexes. In the postoperative period (includ-
ing post-trauma), the therapeutic interventions should be 
focused on providing effective analgesia and haemody-
namic stability. In order to achieve this, perioperative (post-
trauma) opioid analgesics are used. According to some re-
cent studies, however, patients are likely to develop opioid-
induced immunosuppression, which may result in increased 
incidences of perioperative infections, an increased risk of 
complications (in elderly patients, in particular) [120, 121] 
and the risk of opioid-induced hyperalgesia (opioid paradox) 
resulting in higher intensity of pain, despite the escalation 
of doses of opioid analgesics [122, 123]. Moreover, opioid-
induced adverse effects in the perioperative or post-trauma 
period, such as nausea, vomiting, impaired peristalsis, can 
significantly prolong the hospitalisation and favour perio-
perative complications. Therefore, the on-going studies are 
focused on the optimisation of perioperative management, 
in which the use of opioid analgesics will be substantially 
limited or completely eliminated (opioid free anaesthesia/
analgesia — OFA), which should enable the elimination of 
opioid-associated adverse reactions [124–126].
The above method involves multimodal management 
based on multifaceted pharmacotherapy and block anaes-
thesia techniques and is associated with: 
1) the induction of a sympathetic nerve block:
 — direct: clonidine, dexmedetomidine, β-adrenolytics;
 — indirect: lidocaine, volatile anaesthetics, calcium an-
tagonists;
2) the use of multimodal pharmacotherapy modulating 
nociception:
 — ketamine, dexmedetomidine, lidocaine i.v., MgSO4,
 — paracetamol, dexketoprofen, metamizole;
3) peripheral nerve blocks:
 — single/continuous infiltration anaesthesia,
 — interfascial blocks,
 — paravertebral blocks,
 — nerve and plexus blocks;
4) central blocks.
Considering the above, the use of ketamine, whose 
mechanism of action is multifaceted, enables one to 
provide effective OFA or to substantially reduce opioid 
doses. By inhibiting the activation of the NMDA receptor, 
ketamine induces analgesia and prevents the develop-
ment of chronic postoperative pain [127,128] whereas by 
activating adrenergic neurones and inhibiting synaptic 
reuptake of monoamines it determines haemodynamic 
stability in the perioperative and post-trauma period [129, 
130]. Ketamine is also characterised by the lack of inhibi-
tory effects on the respiratory centre; it dilates bronchi-
oles, does not inhibit the upper respiratory reflexes [131] 
and blocks the activation of proinflammatory cytokines 
[132]. Moreover, its use is associated with a significantly 
lower incidence and severity of postoperative nausea and 
vomiting (level IA, according to evidence-base medicine 
(EBM) [133, 134]. Furthermore, the antidepressant action 
of ketamine used in sub-anaesthetic doses, associated 
both with the induction of brain-derived neurotrophic 
factor (BDNF) expression (BDNF concentration is reduced 
in patients with depression) and with glutaminergic neu-
rotransmission block, is particularly useful in ICU patients 
after multiple organ injuries or extensive surgical proce-
dures, as it can prevent post-traumatic stress syndrome 
[135, 136].
In clinical practice, sub-anaesthetic doses of periopera-
tive ketamine are recommended, which provide haemody-
namic stability and effective analgesia, and allow avoiding 
psychotomimetic symptoms. The suggested perioperative 
doses are presented in Table 7 [137].
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Table 7. Perioperative sub-anaesthetic doses of ketamine [137]
Surgical procedures < 60 min; 0.1–0.3 mg kg-1 i.v. bolus during induction
Surgical procedures > 60 min, with no i.v. infusion planned in the postoperative period; 0.1–0.3 mg kg-1 i.v. bolus during induction, followed by 
boluses at a dose of 0.1–0.3 mg kg-1 every 30–60 min
Surgical procedures > 60 min, with i.v. infusion planned in the postoperative period; 0.1–0.3 mg kg-1 i.v. bolus during induction followed by i.v. 
infusion at a dose of 0.1–0.2 mg kg-1 h-1 over 24–72 hours. After 24 hours, a dose reduction to 10 mg h-1 or less should be considered
It should be emphasised that due to the effects de-
scribed above, ketamine is used in emergency medicine 
and battlefield medicine, where it effectively relieves acute 
pain accompanying the injuries to the thorax, abdomen, soft 
tissues and the skeletomuscular system [138–140]. 
The dosing protocol of ketamine in this group of patients 
is as follows: 
 — initial dose: 0.1–0.5 mg kg-1 
 —  followed by continuous i.v. infusion of 0.05–0.4 mg kg-1 h-1 
[140, 141]. 
Moreover, in trauma patients, pre-hospital analgesic 
management involves intranasal applications of S-ketamine 
at a dose of 0.45–1.25 mg kg-1 [142] or racemic ketamine 
at an initial dose of 0.7 mg kg-1; when ineffective within 
15 minutes, another dose is given — at 0.5 mg kg-1 [143].
Acute pain accompanying diagnostic and therapeutic 
procedures in emergency departments and intensive care 
units is relieved with a mixture of ketamine and propofol, 
so-called ketofol, usually in the following doses:
 — 1:4 (40 mg ketamine + 160 mg of propofol),
 — 1:1 (0.5 mg kg-1 ketamine + 0.5 mg kg-1 propofol) [144–
146].
cAnnABInoIdS In PAIn MAnAGEMEnt
Cannabinoids are organic chemical compounds, active 
substances interacting with the metabotropic cannabinoid 
receptors CB1 and CB2, produced endogenously in humans 
and animals – endocannabinoids (anandamide and arachidi-
nyl glycerol), phytocannabinoids found in Cannabis sativa 
and Cannabis indica and synthetic cannabinoids. Cannabi-
noids naturally occurring in cannabis herbs have been used 
for medical purposes for centuries. Marihuana is also the 
most popular narcotic agent used for recreational purposes. 
In the 1940s, the use of cannabinoids was prohibited in the 
United States and many other countries. The active compo-
nent is psychoactive Δ-9-tetrahydrocannabinol (THC), also 
responsible for many known effects; more than 60 chemical 
compounds were identified, including cannabidiol (CBD) 
and cannabinol (CNB) showing no psychoactive action. 
The CB1 receptors located in the CNS and agonists of 
these receptors have euphoric, anti-seizure, analgesic, an-
tiemetic and appetite-enhancing effects. As they are not 
present in the medulla oblongata, cannabinoids do not 
cause respiratory depression. The CB2 receptors are located 
peripherally, have immunosuppressive and anti-inflamma-
tory effects, modulating the release of proinflammatory 
cytokines (among other things). They are present in the 
respiratory and cardiovascular system, muscles and gas-
trointestinal tract. Under normal conditions, cannabinoid 
neurotransmitters (endocannabinoids) bound to cannabi-
noid receptors regulate homeostasis and the maintenance 
of cognitive functions, memory, appetite, heart rhythm, 
intraocular pressure and gastrointestinal peristalsis. 
A systematic review of the available randomised con-
trolled studies demonstrates that cannabinoids do not play 
any role in relieving acute, postoperative pain. Moreover, 
they have not been found to be effective for prevention of 
postoperative nausea and vomiting [147–149].
Cannabinoids may be used in cancer patients with the 
disease-associated symptoms or negative treatment out-
comes, such as persistent nausea, vomiting, loss of appetite 
and pain, mainly neuropathic pain resistant to other forms of 
treatment. The above symptoms are predominantly related 
to chemotherapy and radiation therapy. Pre-clinical stud-
ies suggest that cannabinoids might be also effective for 
prevention of peripheral neuropathy after chemotherapy 
[150–152]. Cannabinoids used for a short time have an ac-
ceptable safety profile and the adverse effects are generally 
well tolerated and short-term. In conclusion, prescription 
cannabinoids should be available for patients with debilitat-
ing symptoms when other standard methods of treatment 
have failed [153, 154].
GEnErAL rEcoMMEndAtIonS
PREOPERATIVE EDUCATION AND PLANNING  
OF PERIOPERATIVE PAIN MANAGEMENT
It is recommended to provide patients with information 
and knowledge of postoperative pain treatment options. 
The plan and goals of postoperative pain management 
should be documented (I C strong recommendation, low-
quality evidence).
An individualised approach to preoperative educa-
tion involves the provision of information that is age-
appropriate, tailored to the patient and family level of 
comprehension, one’s general knowledge about health, 
cultural and linguistic differences, and supported by op-
portunities to ask questions and receive authoritative and 
useful answers [155]. 
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The administration of analgesics should be adjusted 
to the patient and their needs. An individual approach to 
perioperative analgesia should include preoperative evalu-
ation of the patient, a physical examination and an assess-
ment of their history regarding concomitant diseases, in-
cluding mental health, concomitant drugs, the presence of 
chronic pain, earlier strategies of postoperative pain relief 
(I C, strong recommendation low-quality evidence) [156]. 
Moreover, it is important to evaluate opioid dependence 
or tolerance, as well as earlier and present consumption, 
as it may be associated with increased requirements for 
opioids in the postoperative period and inadequate an-
algesia [157]. 
Education or counselling should also include informa-
tion about the way of reporting pain and its assessment 
(including tools for evaluating pain). Moreover, the goal of 
education should be to correct all false beliefs concerning 
pain and analgesics.
In the analgesic management plan, the efficacy of pain 
relief should be so adjusted as to minimise any adverse 
effects (IC strong recommendation, low-quality evidence). 
Optimal pain treatment should be provided with suit-
ably frequent assessment of pain relief adequacy and the 
early detection of adverse reactions (respiratory depression 
requiring immediate intervention) [158]. 
METHODS FOR PAIN INTENSITY ASSESSMENT
In order to monitor one’s responses to analgesic treat-
ment and verify its management (if required), the use of 
validated tools is recommended (scales of postoperative 
pain assessment (I B, strong recommendation moderate-
quality evidence). The tools assessing the severity of pain 
use various methods of pain measurement (scales: visual-
analogue; numerical; verbal). The choice of a scale (tool) 
should be based on such factors as developmental status, 
cognitive status, consciousness level, educational level and 
linguistic differences [159–161]. 
Examples of the recommended subjective assessment 
of pain intensity in adults are as follows:
 — 5-point numerical rating scale (NRS 0–5) [162],
 — 10-point numerical rating scale (NRS 0–10) [163],
 — verbal rating scale (VRS) [163],
 — visual analogue scale (VAS) (0–10 cm or 0–100 mm) [164].
The assessment of pain intensity should be regularly 
monitored not only at rest but also in situations that can 
provoke and intensify pain (which is important and empha-
sised in the literature), e.g. during post-tonsillectomy swal-
lowing, deep breathing and coughing after a thoracotomy 
and abdominal procedures, as well as during walking after 
lower limb surgeries. The pain intensity should not exceed 
an NRS score of 4 (0–10-point scale); in situations provoking 
severe pain, up to 6 [165]. 
If the level of pain severity is high and unresponsive to 
routine management, it should be evaluated whether the 
pain does not result from a new condition, postoperative 
complications or potential tolerance to opioids. The evalu-
ation is to determine which of the interventions is going to 
be effective, the way pain affects the functional changes, 
the type of pain (e.g. neuropathic, visceral, somatic, spastic), 
as well as possible impediments to effective pain treatment 
(cultural or linguistic differences, intellectual limitations or 
false beliefs regarding pain management). 
There is no sufficient evidence to indicate special recom-
mendations concerning the optimal time and frequency of 
re-assessment of postoperative patients. The time of assess-
ment after the intervention should correspond to the period 
in which the maximum efficacy is achieved, most commonly, 
15–30 minutes after parenteral pharmacotherapy or 1–2 
hours after oral analgesic administration. 
MULTIMODAL THERAPY — GENERAL PRINCIPLES 
The concept of multimodal (“balanced”) analgesia was 
introduced for postoperative pain management more than 
20 years ago [166]. The method is defined as the use of a va-
riety of analgesic medications and techniques that target 
many mechanisms of action in the peripheral and/or CNS 
system (also combined with non-pharmacological interven-
tions) resulting in additive or synergistic effects and more 
effective pain relief compared with single-modality inter-
ventions. The suggested analgesic techniques are based 
on regional blocks (peripheral or central) in combination 
with systemic opioids and other analgesics as part of a mul-
timodal approach to postoperative pain management. The 
use of opioid analgesics may not be required in all patients. 
One study has suggested that opioids should be avoided 
when not needed, as there is some evidence demonstrating 
that perioperative opioid therapy may be associated with 
an increased risk of prolonged opioid use and the resultant 
dangers [167]. 
Randomised trials [168, 169] demonstrate that multi-
modal analgesia involving the simultaneous use of several 
combined drugs affecting various receptors, or at least one 
pharmacological method based on different techniques 
(e.g. systemic supply and central blocks), is associated with 
excellent pain relief and reduced requirements for opioids, 
as compared with a single drug administered using one 
technique, even after excluding those trials which were 
retracted due to scientific fraud or those that had not been 
retracted despite their author having admitted falsifying 
the data in other studies [170, 171].
For any given situation, there are numerous potential 
combinations and various multimodal methods that can 
prove effective depending on the type of surgery, individual 
clinical factors and patient`s preferences. Given the dangers 
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associated with opioid use, contraindications or planned 
long-term treatment of postoperative pain, it is recom-
mended to use opioid-free multimodal analgesia based on 
the simultaneous use of several drugs affecting different re-
ceptors in combination with regional techniques [168, 169].
The choice of multimodal therapy is a challenge as many 
potential combinations can be designed for each surgi-
cal procedure, mainly targeted at reducing opioid require-
ments. However, while using multimodal analgesia, anaes-
thetists should be aware of the different side effect profile 
for each analgesic or technique applied. When three or 
more analgesics are combined, it is difficult to draw explicit 
conclusions and anticipate the safety and efficacy of such 
a therapy, due to the diversity of mechanisms of analgesic 
actions, doses, routes of administration, etc. It is essential to 
provide suitable monitoring to identify adverse effects and 
manage them (i.e. to apply effective treatment) [172–174]. 
Multimodal analgesia for postoperative pain manage-
ment, targeted at reducing opioid requirements or elimi-
nating them, is strongly recommended (I A strong recom-
mendation, high-quality evidence).
OPIOID ANALGESICS FOR POSTOPERATIVE PAIN THERAPY
In patients in whom the use of opioids for postoperative 
pain management is required, the enteral route of admin-
istration is recommended, provided that there are no con-
traindications for oral supply (I B strong recommendation, 
moderate-quality evidence).
The majority of evidence suggests intravenous adminis-
tration of opioids in postoperative analgesia is not superior 
to the oral route and is generally preferred [175]. Given the 
continuous nature of postoperative pain during the first 
day and the necessity to initially titrate opioids, long-acting 
opioids are not recommended (due to a lack of evidence 
proving effective pain control). The exception is patients 
receiving long-lasting opioids preoperatively. 
It is not recommended to use preoperative opioids in 
order to reduce the severity of postoperative pain or opioid 
requirements (study findings demonstrate a lack of evident 
benefits [176, 177].
 The intramuscular supply of analgesics (opioid and non-
opioid) for acute and postoperative pain management is not 
advised (I B strong recommendation, moderate-quality evi-
dence) as it may cause a substantial pain at the site of injec-
tion and is associated with unpredictable absorption, which 
restricts the control of postoperative analgesia [178, 179]
PCA for intravenous opioid administration is recom-
mended and necessary in patients with intestinal obstruc-
tion and the risk of aspiration after surgical procedures as 
they cannot take drugs orally (enterally) (I B strong recom-
mendation, moderate-quality evidence). Intravenous PCA 
should be used in the group of patients requiring long-term 
(at least 24h) opioid analgesia whose cognitive functions 
are preserved (understanding the functioning of devices 
and health consequences of this technique, its limitations 
and safety) [180–182].
The use of single intravenous doses of opioids may be 
considered in the immediate postoperative period (the first 
several hours) in order to achieve quick pain relief and to 
titrate analgesic doses. Single intravenous doses may also 
be used in patients under sedation, provided that vital func-
tions are strictly monitored [176]. In the immediate postop-
erative period, intravenous boluses may be considered in 
order to quickly alleviate pain and suitably titrate the opioid 
dose. Possible sequels of this method, i.e. increased seda-
tion or respiratory depression, should be monitored [176]. 
The routine use of basal infusions with i.v. PCA is not 
recommended, particularly in opioid-naive adults (I B strong 
recommendation, moderate-quality evidence) [183, 184]. 
Additionally, the basal infusion of opioids is associated 
with an increased risk of nausea and vomiting, as well as 
respiratory depression [185]. There is still no strong evidence 
about the usefulness of opioid basal infusion in patients 
receiving long-term preoperative opioid therapy. 
It is recommended to monitor appropriately the depth 
of sedation, the efficacy of ventilation and other adverse side 
effects of postoperative opioids (I B strong recommendation, 
moderate-quality evidence). 
Due to the risk of excessive sedation and respiratory 
depression, patients receiving systemic opioids postopera-
tively should be strictly monitored during the first post-
surgery hours and after dose changes [186]. This monitoring 
should include an assessment of the degree of sedation and 
the signs and symptoms of hyperventilation or hypoxia. 
Although the respiratory system is often postoperatively 
monitored using pulse oximetry, it is not clear whether this 
method is superior to the observation of respiratory rates and 
sedation carried out by nurses; randomised trials have not 
proven evident effects on clinical outcomes while the sensi-
tivity of pulse oximetry is too low to identify hyperventilation 
when supplemental oxygen is being administered [187]. 
Limited evidence suggests that capnography may prove 
to be more sensitive than pulse oximetry in detecting respir-
atory depression in patients receiving supplemental oxygen 
[188]. The evidence is insufficient to explicitly recommend 
the use of capnography or other more sophisticated meth-
ods of monitoring. The risk factors of respiratory depression 
include a history of sleep apnoea [189] and the use of other 
CNS-depressive drugs [186].
NON-OPIOID DRUGS FOR ACUTE POSTOPERATIVE PAIN 
MANAGEMENT
Nonsteroidal anti-inflammatory drugs (NSAIDs) are rec-
ommended as part of multimodal analgesia unless there 
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are specific contraindications (IA- strong recommendation, 
high-quality evidence). 
The administration of NSAIDs is associated with an in-
creased risk of gastrointestinal bleeding, cardiologic incidents 
and kidney dysfunction, which should be considered when 
choosing treatment. The literature demonstrates that the 
risk of gastrointestinal disturbances is lower when celecoxib, 
a selective cycloxygenase 2 inhibitor, is used. Although animal 
studies suggest an association between bone non-union after 
orthopaedic surgeries and NSAIDs, there is no strong evi-
dence confirming the effects of NSAIDs on non-union rates. 
Although some observations suggest a possible association 
between high doses of NSAIDs and non-union in spinal fusion 
[186, 190], this association has not been found to be statisti-
cally significant in the analysis of strong-evidence studies. 
Observational studies suggest that exposure to NSAIDs may 
be associated with an increased risk of anastomotic leakage 
after colon surgeries [191–193]. No sufficient evidence has 
been found to recommend against the use of NSAIDs in pa-
tients undergoing surgeries for orthopaedic fractures, spinal 
fusion and colon procedures. There are contraindications for 
NSAID use in postoperative pain management in patients 
undergoing coronary artery bypass grafting procedures due 
to an increased risk of cardiovascular incidents [194]. 
It is recommended to administer a preoperative oral 
dose of celecoxib in adults, unless contraindicated (IB strong 
recommendation, moderate-quality evidence).
Celecoxib reduces opioid requirements after surgery; 
moreover, many studies have reported significantly reduced 
postoperative pain [195–197]. 
It is recommended to consider the use of gabapentin 
or pregabalin as a component of multimodal therapy (I B 
strong recommendation, moderate-quality evidence) in 
order to reduce postoperative opioid requirements and to 
achieve the direct analgesic effect [198–200].
It is suggested to supply gabapentinoids, particularly in 
patients undergoing surgeries associated with substantial 
pain or as part of multimodal therapy in patients with a high 
tolerance to opioids. The possible adverse effects include 
nausea and sedation that is not connected with respiratory 
depression. Dose reductions are recommended in patients 
with kidney dysfunction.
Moreover, intravenous ketamine is recommended to be 
considered as part of multimodal therapy (II B weak recom-
mendation, moderate-quality evidence).
The available study findings have demonstrated that 
intravenous infusions of ketamine were associated with re-
duced postoperative requirements for analgesics, compared 
with a placebo; according to some studies, the supply of this 
drug was associated with a lower severity of postoperative 
pain. Intravenous ketamine was also associated with a lower 
risk of persistent postoperative pain [201–203].
There is no explicit evidence to determine the optimal 
method of ketamine dosing. A single preoperative dose of 
0.5 mg kg-1 is recommended, followed by intraoperative 
infusion of 10 µg kg-1 min-1 with or without postopera-
tive infusion at a lower dose [204]. The principles of its use 
should be known and adverse reactions taken into account 
(hallucinations, nightmares). It is suggested that ketamine 
should be reserved for extensive surgical procedures, espe-
cially in highly opioid-tolerant patients and those in whom 
non-opioid analgesia is indicated. 
Intravenous lidocaine is recommended in adults under-
going open and laparoscopic abdominal procedures, taking 
into account contraindications (II B weak recommendation, 
moderate-quality evidence).
Intravenous lidocaine is recommended as part of mul-
timodal perioperative analgesia in abdominal surgeries 
with the available study findings demonstrating a shorter 
duration of gastrointestinal motoric dysfunction and better-
quality analgesia, as compared with a placebo [205, 206]. In 
clinical trials, lidocaine was usually administered in a bolus 
(100–150 mg or 1.5–2.0 mg kg-1), followed by an infusion of 
2–3 mg kg-1 h-1 until the completion of surgery. Ultimately, 
an induction dose of 1.5 mg kg-1 and an intraoperative dose 
of 2 mg kg-1 h-1 are recommended [207, 208]. The continu-
ation of intravenous infusion in the postoperative period 
requires further studies. 
LOCAL ANALGESIA
Surgical site infiltration with a local anaesthetic is recom-
mended for procedures in which local anaesthetics were 
proved to be effective (II B weak recommendation, moder-
ate-quality evidence). Subcutaneous and/or intra-articular 
local anaesthesia of the surgical site has been demonstrated 
to be an effective element of multimodal analgesia in nu-
merous surgical procedures, including knee replacements, 
knee arthroscopic procedures, Caesarean sections, laparoto-
mies and haemorrhoid surgeries [209–211]. 
The use of surgical site local infiltration should be based 
on evidence showing a benefit in a given surgical procedure. 
It is essential to have appropriate knowledge concerning the 
method of infiltration and its range, which differ depending 
on the surgery and other local anaesthetics used, including 
those of extended release such as liposomal bupivacaine 
[212]. Moreover, although data are limited, continuous intra-
articular bupivacaine in patients undergoing shoulder pro-
cedures can be associated with chondrolysis [213], which 
suggests caution while using this method. 
PERIPHERAL NERVE BLOCKS
Peripheral nerve blocks are recommended as regional 
analgesia for surgeries in which the evidence shows their 
efficacy (I A strong recommendation, high-quality evidence).
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It has been demonstrated that peripheral blocks are an 
effective component of multimodal analgesia for postop-
erative pain management in numerous surgical procedures, 
including thoracotomy [214], lower limb arthroplasty [215–
217] shoulder surgeries [216] and Caesarean sections [218].
A precondition for safe and effective use of peripheral 
nerve blocks is appropriate knowledge regarding the use of 
ultrasound imaging and anatomy, as well as the mechanisms 
of action of local anaesthetics and their adverse effects. 
Potential motor blocks and the risk of falls should be taken 
into account. When continuous blocks using elastomeric 
pumps (which, unlike electronic pumps, are not equipped 
with an alarm) are decided upon, the patient and/or car-
egivers should be instructed about the functioning of such 
a pump and the symptoms of toxic reactions induced by 
local anaesthetic overdosing. 
Continuous methods of peripheral nerve blocks are 
recommended exclusively when the required duration of 
analgesia exceeds the time of action of a single injection 
(I B strong recommendation, moderate-quality evidence).
Both a single injection and continuous peripheral blocks 
are effective for postoperative analgesia in patients under-
going various surgical procedures [216, 219]. If the duration 
of postoperative pain is prolonged, continuous blocks are 
generally preferred to a single injection whose action is 
limited. 
CENTRAL BLOCKS 
Central blocks are recommended for postoperative an-
algesia after thoracic and abdominal surgeries, particularly 
in patients at high risk of cardiac and pulmonary complica-
tions and prolonged ileus (I A strong recommendation, 
high-quality evidence) [214, 220].
As far as the preventive effect is concerned, there are 
data demonstrating the efficacy of central blocks in chronic 
postoperative pain. In order to prevent chronic postopera-
tive pain, it is recommended to use epidural anaesthesia 
after a thoracotomy and paravertebral anaesthesia for mas-
tectomies [221]. The decision to use epidural analgesia for 
postoperative pain management has to be associated with 
numerous factors, while the medical personnel should con-
sider the risk-benefit ratio. Moreover, adequate monitoring 
of patients should be provided (I B strong recommendation, 
moderate-quality evidence). 
Although epidural analgesia is associated with a lower 
risk of perioperative mortality, as well as cardiac and pulmo-
nary complications, as compared with systemic opioids, the 
adverse effects and complications of this method should be 
taken into account (respiratory depression, hypotension, 
epidural haematoma or abscess) [214]. In patients under-
going hip or lower extremity surgical procedures, central 
blocks may mask the symptoms of tunnel syndrome. Due 
to the above-mentioned effects of central blocks, patients 
should be monitored and the attending personnel should be 
prepared to implement the methods for the prevention and 
treatment of adverse effects and complications (reduction in 
drug doses, catheter removal in cases of haematomas or ab-
scesses) or to undertake some other measures, as required. 
PAIN CONTROL TEAMS — STRUCTURE AND FUNCTIONING
The centres in which surgical procedures are performed 
are recommended to have an organisational structure (or 
re-organise the existing one) in order to develop and im-
prove the management policy of safe and effective postop-
erative pain relief (I C strong recommendation, low-quality 
evidence).
The centres in which surgical procedures are performed 
should have an organisational structure in order to over-
see the development, implementation and assessment of 
principles and practices in order to assure safe, evidence-
based and effective postoperative pain control. Ideally, the 
process should be interdisciplinary, provided by already 
existing organs or a designated pain control team. The role 
of administrative and medical management is emphasised, 
including the units that are most integrally connected with 
perioperative pain management. Access to specialist con-
sultations should be provided for patients with inadequate 
postoperative pain management or those at high risk of in-
adequate postoperative pain management (e.g. a history of 
opioid tolerance or dependence or chronic pain) (I C strong 
recommendation, low-quality evidence).
Postoperative pain treatment can be a challenge and 
requires the advanced methods of assessment and manage-
ment skills that specialists in pain therapy possess. In some 
cases, postoperative pain may be controlled inadequately 
despite the use of standard multimodal therapies [222]. 
 Centres using advanced techniques of central and pe-
ripheral blocks should have appropriately educated per-
sonnel and ensure training, supervision and the gaining of 
experience in order to assure safe and effective treatment. 
Those centres employing advanced techniques of postop-
erative analgesia should have clearly defined policies and 
procedures ensuring the adequate monitoring of patients 
and competent, well-trained and educated personnel in-
volved in caring for these patients. Moreover, clear and 
reliable principles for hospital and nursing staff to be able 
to contact specialists employing the above-mentioned tech-
niques should be defined (I C strong recommendation, low-
quality evidence).
POST-HOSPITAL POSTOPERATIVE PAIN CONTROL
It is recommended that physicians provide both patients 
(or legal guardians) and staff ensuring basic health care with 
information regarding pain therapy plans, including the 
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gradual reduction of analgesic doses after discharge (I C 
strong recommendation, low-quality evidence).
Studies on the methods and outcomes of discharge 
planning are few and insufficient to recommend particular 
optimal methods [223]. Nevertheless, the available reports 
and clinical experience suggest the need for proper co-
ordination of actions after discharge, as part of a postop-
erative pain management plan. A coordinated approach 
to recommendations after discharge is highly important, 
including advice and support from family doctors, nurses, 
physiotherapists and pharmacists [224]. 
dEtAILEd rEcoMMEndAtIon — AnALGESIc 
MAnAGEMEnt In SELEctEd tYPES oF SurGErIES
The recommendations do not include doses of indi-
vidual drugs (they should be used in accordance with the 
Summary of Product Characteristics or the suggestions of 
the authors presented in the remaining chapters of the 
recommendations, based on the 2014 guidelines which 
described the doses of all drugs in detail).
ARTHROSCOPIES, ENDOSCOPIC UROLOGICAL 
PROCEDURES, SKIN AND SUBCUTANEOUS TISSUE 
PROCEDURES
 — paracetamol and/or
 — nonsteroidal anti-inflammatory drugs (NSAIDs):
a)  coxibs or
b)  selective NSAIDs: nimesulide, meloxicam or
c)  non-selective NSAIDs (diclofenac, or ibuprofen or 
ketoprofen or dexketoprofen) 
and/or 
d)  metamizole and /or 
e)  tramadol (capsules, drops). 
All the above analgesics are recommended for oral ad-
ministration. During the following postoperative days, the 
number of drugs should be gradually reduced (without 
reducing the doses), taking into account the severity of pain 
reported by the patient. 
Techniques of local analgesia: 
 — adductor canal block (knee arthroscopy, 20 mL 2% li-
docaine or 20 mL 0.375% ropivacaine or 0.375–0.25% 
bupivacaine);
 — brachial plexus block (shoulder arthroscopy, 10–15 mL 
2% lidocaine or 0.375–0.5% ropivacaine or 0.375–0.5% 
bupivacaine) or 
 — axillary and suprascapular nerve block (shoulder ar-
throscopy, 5–10 mL per each nerve, 2% lidocaine, or 
0.375% ropivacaine, or 0.25% bupivacaine); 
 — surgical incision injection with a local anaesthetic (1–2% 
lidocaine, 0.2% ropivacaine, 0.125–0.25% bupivacaine, 
in a volume dependent on the extent of the incision, 
and not exceeding maximum doses).
LAPAROSCOPIC CHOLECYSTECTOMY, APPENDECTOMY, 
INGUINAL HERNIA REPAIR, STRUMECTOMY 
Before surgery: 
 — nonsteroidal anti-inflammatory drugs (NSAIDs): 
a)  coxibs (B) or
b)  selective NSAIDs: nimesulide, meloxicam (p.o.) (C) or
c)  non-selective NSAIDs (diclofenac or ibuprofen or ke-
toprofen or dexketoprofen) (p.o.) (A);
 — dexamethasone (i.v.) (B);
 — gabapentin (p.o.) (B);
 — lidocaine (i.v.) (B).
Local techniques:
 — ilioinguinal and iliohypogastric nerve block (B) (10–15 
mL of local anaesthetics , e.g. 0.2% ropivacaine, or 1–2% 
lidocaine, 0.1–0.125% bupivacaine) or
 — incision site infiltration 0.25–0.5% ropivacaine 30–40 mL 
or 0.25–0.5% bupivacaine up to 30 mL (A) or
 — quadratus lumborum block (QLB) (15–20 mL), 0.2% 
bupivacaine or 0.375% ropivacaine (C) (inguinal hernia 
repair, traditional method);
 — trocar site injection with local anaesthetics (LAs) (A) 
(laparoscopic procedures); 
 — incision site injection with LAs (0.25–0.5% ropivacaine 
10–20 mL, 0.25–0.5% bupivacaine 10–20 mL) (A) 
(strumectomy).
After surgery: 
 — paracetamol and/or metamizole (A) and/or
 — NSAIDs (ketoprofen or dexketoprofen or coxibs [no 
contraindication and possible oral administration]) (A);
 — weak opioids (C) — tramadol;
 — strong opioids (morphine, oxycodone) as rescue anal-
gesia (C) [225].
In cases of high risk of pulmonary complications, tho-
racic epidural analgesia is recommended (laparoscopic 
cholecystectomy) (B).
Parenteral postoperative analgesia should be replaced with 
non-invasive methods of administration (enteral) as quickly as 
possible; opioids should be replaced with non-opioid analge-
sics and the intensity of pain ought to be regularly controlled. 
TONSILLECTOMY
Before surgery: 
 — nonsteroidal anti-inflammatory drugs: 
a)  coxibs (B) or
b)  selective NSAIDs: nimesulide (p.o.) (C) or
c)  non-selective NSAIDs (ibuprofen) (p.o.) (C);
 — dexamethasone (i.v.) (B);
 —  gabapentin (p.o.) (C).
After surgery: 
 — paracetamol and/or metamizole (A);
 — and/or NSAIDs (ketoprofen or dexketoprofen or coxibs 
[no contraindication and possible oral administration]) (A);
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 — weak opioids (C) (tramadol);
 — strong opioids (morphine, oxycodone) as rescue anal-
gesia (C).
Local techniques: 
 — post-tonsillectomy site injection 5–7 mL per side: 0.25–
0.375% bupivacaine or 0.5% ropivacaine, or 2% lidocaine 
[227–231]. 
CAESAREAN SECTION
Before surgery:
 — gabapentin (p.o.) (I A);
 — dexamethasone (i.v.) (II B).
After surgery: 
 — paracetamol (i.v.) (I A);
 — morphine (i.v.) (PCA) (I A);
 — or nalbuphine (i.v.) (PCA) (II B).
Local analgesia:
 — quadratus lumborum block (QLB) (15–20 mL per side), 
0.2% bupivacaine or 0.375% ropivacaine (C) or 
 — transversus abdominis plane (TAP) block, 15–20 mL 
per side 0.125–0.25% bupivacaine or 0.2–0.375% ropi-
vacaine (C) or 
 — wound injection or continuous infiltration with LAs (IA) 
[231–234].
MASTECTOMY
Before surgery: 
 — paravertebral block (paravertebral blockade — PVB) (A);
 — pectoral nerve blocks PECS 1 PECS 2 (pectoral nerve 
blocks 1, 2) 10–20 mL 0.2% ropivacaine or 0.1% bupiva-
caine, serratus anterior plane block (SAPB 1, 2);
 — gabapentin (p.o.) (A);
 — coxibs (p.o.) (C);
 — paracetamol (p.o.) (B).
After surgery: 
 — (VAS > 5) NSAIDs or coxibs (A) + paracetamol (B) + strong 
opioids (B) and/or metamizole;
 — (VAS > 3 < 5) NSAIDs or (A) + paracetamol (B) + weak 
opioids (B) and/or metamizole.
Local analgesia:
 — continuation of continuous PVB analgesia (A)
or continuous thoracic segmental blocks (C) [235–237].
THORACOTOMY
Before surgery:
 — thoracic epidural anaesthesia/analgesia (TEA) with LA 
+ strong opioid (A) or 
 — paravertebral block (PVB) with LA (A) or 
 — intercostal block (C) or 
 — one of the thoracic peripheral blocks (QLB or ESP or 
PECS 1 and 2) (C);
 — phrenic nerve block (C) (prevents and reliefs shoulder 
pain);
 — incision site infiltration with LA (A).
 After surgery:
 — TEA continuation (continuous infusion or PCA) (A) or 
 — PVB continuation (continuous infusion PCA) (A) or 
 — systemic analgesia (no possibility to perform or lack of 
efficacy of regional analgesia);
a)  non-selective NSAIDs (i.v.) (A) or 
b)  coxibs (p.o.) (B);
c)  strong opioids (i.v. PCA) (A) + NSAID (A) + paracetamol (A) or 
d)  weak opioids (i.v.) (C) + NLPZ + metamizole + para-
cetamol [238–241].
LAPAROTOMY
Before surgery:
 — coxibs (p.o.) (B);
 — lidocaine (i.v.) (B);
 — thoracic epidural anaesthesia (PCA) (A) or 
 — bilateral TAP block (15–20 mL per side 0.125–0.25% 
bupivacaine or 0.2–0.375%) ropivacaine (C) or 
 — bilateral QLB (15–20 mL per side, 0.2% bupivacaine or 
0.375% ropivacaine) (C) or 
 — before closure of integuments — injection or supraperi-
toneal continuous infiltration (B). 
After surgery:
 — TEA continuation (A) or 
 — NSAID (i.v.) (A) + lidocaine (i.v.) (B) + strong opioid (i.v. 
PCA) (B) or
 — NSAID (i.v.) (A) + lidocaine (i.v.) (B) + weak opioid (i.v.) 
(B) + paracetamol (i.v.) (B) + metamizole (i.v.) (B) [242].
RADICAL PROSTATECTOMY
Before surgery:
 — coxibs (B);
 — gabapentin (B);
 — dexamethasone (B);
 — lidocaine (i.v.) (C).
After surgery:
 — local analgesia: incision line injection with LA (B);
 — coxibs (p.o.) (B);
 — lidocaine (i.v.) (B);
 — strong opioids (i.v. PCA) (B) + coxibs (C) + paracetamol 
(i.v.) (C) or 
 — weak opioids (i.v.) (B)+ paracetamol (i.v.) (B) + metami-
zole (i.v.) (B).
HIP PROSTHESOPLASTY
Before surgery: 
 — lumbar epidural analgesia (LEA) only in patients at high 
risk of pulmonary complications;
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 — subarachnoid anaesthesia with LA + opioid (A)
or fascia iliaca peripheral blocks(A). 
After surgery:
 — continuation of LEA or
 — coxibs (p.o.) (A) or 
 — NSAID (i.v. or p.o.) (B) + strong opioids (i.v. PCA) (B) + 
paracetamol (i.v. or p.o.) (A) or 
 — NSAID (p.o.) (B) + weak opioids (p.o. or i.v.) (B) + par-
acetamol (i.v. or p.o.) (A) + metamizole (i.v. or p.o.) (B).
KNEE PROSTHESOPLASTY
Before surgery:
 — general anaesthesia + continuous femoral nerve or ad-
ductor canal block (A);
 — subarachnoid anaesthesia + femoral nerve or adductor 
canal continuous block(A);
 — dexamethasone (i.v.) (C);
 — gabapentin (p.o.) (C);
 — ketamine (i.v. 0.25–0.5 mg kg-1) (C).
After surgery:
 — continuation of peripheral continuous block (continu-
ous infusion or PCA);
 — NSAID (coxibs) (A);
 — strong opioids (i.v. PCA) (A) + paracetamol (i.v. or p.o.) (B);
 — weak opioids (i.v. or PCA) + paracetamol (i.v. or p.o.) (B) 
+ metamizole (i.v. or p.o.) (C) [243–246].
ANORECTAL PROCEDURES
Before surgery: 
 — gabapentin (p.o.) (C);
 — ketamine (i.v.) (C);
 — subarachnoid anaesthesia with LA + opioid or 
 — perirectal infiltration with LA (e.g. 0.25–0.5% ropiv-
acaine, 30–40 mL or 0.25–0.375% bupivacaine up to 
30 mL) (A) or 
 — pudental nerve block (A).
After surgery:
 — NSAIDs (coxibs) + paracetamol + strong opioids (B) or 
 — NSAIDs (coxibs) + weak opioids + metamizole (B).
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